araag2/HINT huggingface dataset:
Clinical trial NCT00488618 (phase 2, status: completed)
Conditions: bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: cariprazine (rgh-188), placebo
SMILES: CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female inpatients 18 to 65 years of age

          -  Meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text
             Revision (DSM-IV) criteria for bipolar I disorder, acute manic or mixed episode

          -  Having a total Young Mania Rating Scale (YMRS) score >= 20 and a score of at least 4
             on two of the following YMRS items:

               -  Irritability,

               -  Speech,

               -  Content, and

               -  Disruptive/Aggressive Behavior

        Exclusion Criteria:

          -  Patients who exhibit abnormalities on physical examination, have abnormal vital-signs,
             electrocardiogram (ECG), or clinical laboratory values [such as thyroid-stimulating
             hormone (TSH)].

          -  Patients with Montgomery-Åsberg Depression Rating Scale (MADRS) total score >= 18 at
             Visit 2.

          -  Patients experiencing first manic episode.

          -  Patients that have received electroconvulsive therapy (ECT) or a depot neuroleptic in
             the 3 months prior to Visit 1.
Clinical trial NCT00254254 (phase 2, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: exenatide - exenatide - placebo, exenatide - placebo - exenatide, placebo - exenatide - exenatide
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Treatment with diet and exercise alone or a stable dose of metformin, or sulfonylurea,
             or metformin plus a sulfonylurea for at least 3 months.

          -  Has HbA1c 6.0% to 11.0%, inclusive, at screening.

          -  Has a body weight of >= 50 kg at screening.

        Exclusion Criteria:

          -  Received any investigational drug or has participated in any type of clinical trial
             within 3 months prior to screening.

          -  Currently participates in any other interventional study.

          -  Is currently treated with any of the following excluded medications:

               -  Sulfonylurea chlorpropamide

               -  Thiazolidinedione within 3 months of screening.

               -  Αlpha glucosidase inhibitor within 3 months of screening.

               -  Meglitinide within 3 months of screening.

               -  Insulin within 3 months of screening.

               -  Pramlintide within 3 months of screening.
Clinical trial NCT00661180 (phase 2, status: completed)
Conditions: chronic myelogenous leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: nexavar (sorafenib, bay43-9006)
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria:- Have Philadelphia chromosome positive chronic myelogenous leukemia
        (CML) in chronic phase, as per IBMTR criteria- Have documented hematologic resistance to
        Gleevec (Imatinib) following a prior hematologic response to Gleevec administered at doses
        of at least 400 mg/d for at least 3 months.- Have WBC >20 x 109/L at study entry- Have an
        ECOG performance status. Status of 0, 1 or 2- Have an anticipated survival of at least 16
        weeks.- Be able to comply with study procedures and follow-up examinations.- Signed
        informed consent must be obtained prior to any study specific procedures. Exclusion
        Criteria:- Congestive heart failure > class II as defined by the New York Heart Association
        Functional Classification (NYHA)- Cardiac arrhythmias requiring antiarrythmics (excluding
        beta blockers or digoxin)- Active coronary artery disease or ischemia- History of HIV
        infection or chronic hepatitis B or C - Active clinically serious infections (> grade 2
        NCI-CTC)- Patients with seizure disorder requiring anti-epileptic drugs- History of solid
        organ allograft
Clinical trial NCT00711503 (phase 2/phase 3, status: completed)
Conditions: type 1 diabetes
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: anakinra, saline
SMILES: COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Type 1 diabetes diagnosed according to WHO 1999 criteria

          -  Positive GAD auto-antibodies

          -  Age 18-35 yrs at onset of diabetes

          -  Time from first symptoms of diabetes < 12 weeks

          -  Peak C-peptide more than or equal to 200 pM after a standardized mixed meal test
             (Boost) at a test carried out when the subject is metabolically stable, i.e. after
             resolution of any polyuria, polydypsia or ketoacidosis.

        Exclusion Criteria:

          -  Severe liver or renal disease (creatinine > 100 μmol/L, ASAT/ALAT > 2* ULN, alkaline
             phosphatase > 2 * ULN)

          -  History of heart disease, signs of cardiac failure or abnormal ECG

          -  Present or previous malignancy

          -  Pregnancy or failure of fertile female to comply with contraceptional planning, or
             breast-feeding. (Safe contraceptive methods include birth control pills, IUD, and
             gestagen implants) . Plans of pregnancy within 2 years.

          -  Participation in other clinical intervention studies

          -  Anti-inflammatory therapy (except aspirin £ 100 mg/d)

          -  Active infections (CRP>30), history of recurrent infection or predisposition to
             infections

          -  Neutropenia: ANC < 1.5*109/L, or anaemia: Haemoglobin < 8.0 g/dL

          -  Immune-suppressive treatment or immune-deficiency

          -  Presence at diagnosis of late diabetic complications

          -  Concurrent vaccination with live vaccine. Known need for live vaccinations within 2
             years.

          -  Use of Etanercept within 6 months before screening or during the double-blinded study
             period

          -  Hypersensitivity to E. coli-derived proteins, anakinra or any components of the
             product.
Clinical trial NCT00002922 (phase 2, status: completed)
Conditions: head and neck cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: paclitaxel
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically proven squamous cell carcinoma of the head and neck
        (including nasopharynx) that is considered incurable with surgery or radiation therapy
        Bidimensionally measurable disease Patients whose only site of measurable disease is within
        a previous radiation port must have documented progressive disease or biopsy-proven
        recurrence after the completion of radiotherapy No uncontrolled CNS metastases

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0 or 1 Hematopoietic:
        Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic:
        Bilirubin no greater than 1.5 mg/dL Renal: Creatinine no greater than 1.5 mg/dL OR
        Creatinine clearance at least 60 mL/min Calcium normal No history of hypercalcemia
        Cardiovascular: No history of ventricular arrhythmias or symptomatic bradyarrhythmia Other:
        No significant detectable infection Not pregnant or nursing No other active malignancies
        Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior interleukin-2, interferons, and
        monoclonal antibodies allowed Recovered from prior therapy Chemotherapy: Prior paclitaxel
        infusion no greater than 24 hours for recurrent or metastatic disease required Endocrine
        therapy: Not specified Radiotherapy: Recovered from prior radiotherapy Surgery: Recovered
        from any prior major surgery
Clinical trial NCT00256880 (phase 2, status: completed)
Conditions: carcinoma, renal cell
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: gw786034
SMILES: CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1
Eligibility criteria:

        Inclusion criteria:

          -  Must have diagnosis of relapsed or refractory multiple.

          -  bone marrow function [ANC (absolute neutrophil count) greater than 1000/mm3]; platelet
             count greater than or equal to 75,000/mm3.

          -  renal function (calculated creatinine clearance >50 mL.min, albumin less than or equal
             to 500 mg).

        Exclusion criteria:

          -  Failed more than 3 prior lines of therapy including stem cell transplant.

          -  Females who are pregnant or nursing.

          -  Unstable blood pressure.

          -  Significant heart conditions or history of thrombosis.

          -  Any unstable, pre-existing major medical condition or history of other cancers.

          -  Have received an investigational drug, chemotherapy, radiation treatment or surgery
             within 28 days prior to entering the study.
Clinical trial NCT00117208 (phase 2, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: mannitol, mannitol + pulmozyme, dornase alpha
SMILES: OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
Eligibility criteria:

        Inclusion Criteria:

          -  Known diagnosis of cystic fibrosis (sweat test or genotype)

          -  Of either gender

          -  Aged between 8 and 18 years

          -  Have a baseline FEV1 of <70% of the predicted normal value

          -  Currently taking rhDNase for at least 4 weeks

        Exclusion Criteria:

          -  Currently active asthma, uncontrolled hypertension, colonised with Burkholderia
             cepacia or MRSA

          -  Listed for transplantation

          -  Known intolerance to mannitol, rhDNase or bronchodilators
Clinical trial NCT01040403 (phase 2, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: olodaterol (bi 1744) low, low tiotropium bromide, olodaterol (bi 1744) high, medium tiotropium bromide, high tiotropium bromide, placebo
SMILES: COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          1. All patients must sign an informed consent

          2. All patients must have a diagnosis of chronic obstructive pulmonary disease (COPD)
             must meet the following spirometric criteria:

        a post-bronchodilator forced expiratory flow in 1 second (FEV1) =<30% of predicted normal
        and <80% of predicted normal and a post bronchodilator FEV1 / forced vital capacity (FVC)
        <70% at Visit 1 4. Male or female patients, 40 years of age or older. 5. Patients must be
        current or ex-smokers with a smoking history of more than 10 pack years

        Exclusion criteria:

          -  Patients with a significant disease other than COPD;

          -  Patients with clinically relevant abnormal baseline haematology, blood chemistry, or
             urinalysis;

          -  Patients with a history of asthma or a total blood eosinophil count >=600/mm3.

          -  Patients with any of the following conditions:

        a diagnosis of thyrotoxicosis (due to the known class side effect profile of ß2-agonists) a
        diagnosis of paroxysmal tachycardia - Patients with any of the following conditions: a
        history of myocardial infarction within 1 year of screening visit a diagnosis of clinically
        relevant cardiac arrhythmia a malignancy for which patient has undergone resection,
        radiation therapy or chemotherapy within last five years

          -  Patients who have undergone thoracotomy with pulmonary resection

          -  Patients being treated with the following concomitant medications:

        medications that prolong the QT/QTc interval oral Beta-adrenergics oral corticosteroid
        medication at unstable doses (i.e., less than six weeks on a stable dose) or at doses in
        excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day

        - Pregnant or nursing women
Clinical trial NCT01403376 (phase 2, status: completed)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: teriflunomide, interferon-β-1
SMILES: C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

        - Male or female patient <60 years old with relapsing multiple sclerosis (RMS) either
        treated for at least 6 months with 7 or 14 mg teriflunomide in one of the studies LTS6048
        or LTS6050, or treated with a stable dose of interferon-β-1 for at least 6 months.

        Exclusion Criteria:

          -  Concomitant infectious pathology at the time of vaccination;

          -  MS relapse within 1 month before vaccination;

          -  Systemic corticosteroids within 1 month before the vaccination;

          -  Any contraindication to influenza vaccine;

          -  Any vaccination within the last 6 months;

          -  Prior use of any investigational drug or participation to a clinical trial within 1
             year (only for patients under interferon-β-1);

          -  Prior or concomitant use (for a minimum of 1 year before study entry) of cladribine,
             mitoxantrone, or other immunosuppressant agents such as azathioprine,
             cyclophosphamide, cyclosporin, methotrexate, mycophenolate, natalizumab (Tysabri®),
             leflunomide or fingolimod or other immunomodulator/immunosuppressant in development;

          -  Prior or concomitant use of glatiramer acetate within 1 year before study entry;

          -  Prior or concomitant use of intravenous immunoglobulins within 3 months before study
             entry;

          -  Pregnant or breast feeding women;

          -  Woman of childbearing potential without adequate contraception.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00612040 (phase 2, status: completed)
Conditions: diabetes, diabetes mellitus, type 1
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: insulin degludec, insulin degludec, insulin glargine, insulin aspart
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 1 diabetes for at least one year

          -  HbA1c 7-11% (both inclusive)

          -  Treated with insulin for at least six months - any regimen

        Exclusion Criteria:

          -  Any systemic treatment with products which in the Investigator's opinion could
             interfere with glucose or lipid metabolism (eg systemic corticosteroids) 3 months
             prior to randomisation

          -  Subject has a clinically significant, active (during the past 12 months) disease of
             the gastrointestinal, pulmonary, neurological, genitourinary, or haematological system
             that, in the opinion of the Investigator, may confound the results of the trial or
             pose additional risk in administering trial product
Clinical trial NCT00206492 (phase 2, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: iressa, tamoxifen
SMILES: COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1, OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
Reason stopped: 
    halted by the pi only 3 of 45 subjects were accrued.
  
Eligibility criteria:

        Inclusion Criteria:

          1. All patients must be female and must have signed an informed consent form.

          2. Primary breast cancers must be human epidermal growth factor receptor (HER2)
             overexpressing (2+ or 3+, or both, as determined by immunohistochemistry [IHC]), and
             estrogen receptor (ER) positive. Primary breast cancers must be of clinical and/or
             radiologic size >4 cm, with or without gross metastatic disease according to the
             International Union against Cancer (UICC) modified World Health Organization (WHO)
             criteria.

          3. Negative serum pregnancy test (bHCG) within 7 days of starting study, if of
             child-bearing potential.

          4. Adequate bone marrow function:

               -  Hematocrit >30%,

               -  total neutrophil count must be >1.5 x 10^9/L, and

               -  platelet count >100 x 10^9/L.

          5. Renal function tests:

               -  creatinine within 1.5 times the institution's upper limit of normal (ULN).

          6. Liver function tests:

               -  Total serum bilirubin within ULN,

               -  liver transaminases within 2.5 x ULN,

               -  alkaline phosphatase within 5 x ULN.

          7. Performance status (WHO scale) <2.

          8. Age > 18 years.

        Exclusion Criteria:

          1. Pregnancy or unwillingness to use a reliable contraceptive method in women of
             child-bearing potential.

          2. Women who are lactating or breastfeeding.

          3. Severe underlying chronic illness or disease.

          4. Patients on other investigational drugs while on study will be excluded.

          5. Severe or uncontrolled hypertension, history of congestive heart failure, acute
             myocardial infarction, or severe coronary arterial disease.

          6. No previous or current malignancies at other sites within the preceding 5 years, with
             the exception of adequately treated, cone-biopsied in situ carcinoma of the cervix
             uteri and basal or squamous cell carcinoma of the skin.

          7. Any evidence of ongoing interstitial lung disease.

          8. Concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or St John's
             Wort.

          9. Treatment with a non-approved or investigational drug within 30 days before Day 1 of
             study treatment.

         10. Known severe hypersensitivity to ZD1839 or any of the excipients of this product.
Clinical trial NCT00273312 (phase 2, status: completed)
Conditions: hepatocellular carcinoma
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: patupilone
SMILES: [H]\C(=C(\C)[C@]1([H])C[C@]2([H])O[C@]2(C)CCC[C@]([H])(C)[C@]([H])(O)[C@@]([H])(C)C(=O)C(C)(C)[C@@]([H])(O)CC(=O)O1)C1=CSC(C)=N1
Eligibility criteria:

        Inclusion criteria:

        - Hepatocellular carcinoma patients with at least 1 previously un-irradiated, measurable
        lesion without any systemic single agent or combination chemotherapy. Previous local
        therapy is allowed.

        Exclusion criteria:

        Additional protocol-defined inclusion/exclusion criteria apply.
Clinical trial NCT00616798 (phase 2, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: ro4917838, ro4917838, ro4917838, placebo, standard antipsychotic therapy
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, 18-60 years of age;

          -  diagnosis of schizophrenia (based on screening tests);

          -  outpatients, with no hospitalization for worsening of schizophrenia within 3 months;

          -  medically and psychiatrically stable over prior 1 month and psychiatrically stable
             without symptom exacerbation within prior 3 months;

          -  currently taking no more than 2 antipsychotic drugs.

        Exclusion Criteria:

          -  began a new non-medication treatment for schizophrenia or other psychiatric condition
             within last 3 months;

          -  on >1 antidepressant, or a change in dose of antidepressant within 3 months;

          -  alcohol or substance abuse or dependence within 3 months;

          -  has previously received RO4917838.
Clinical trial NCT00216164 (phase 2, status: terminated)
Conditions: lymphoma, b-cell
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: rituximab, gemcitabine
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    study terminated due to lack of response at the first efficacy analysis
  
Eligibility criteria:

        Inclusion Criteria:

          -  Biopsy-proven DLBCL which meet the criteria of any of the 4 subgroups

          -  Transformed DLBCL from a previous indolent NHL which meet the criteria of any of the 4
             subgroups and have received at least one standard chemotherapy regimen for aggressive
             NHL or a biopsy upon progression of disease has been obtained to confirm the presence
             of DLBCL. The concomitant presence of a component of low grade lymphoma will NOT
             exclude participation

          -  Measurable disease per Standardized Response Criteria for Non-Hodgkin's Lymphoma

          -  Prior gemcitabine therapy is allowed.

          -  Negative pregnancy test

        Exclusion Criteria:

          -  No history of life-threatening reactions to rituximab.

          -  No history of gemcitabine intolerance; prior gemcitabine therapy is allowed.

          -  No history of malignancy in the last 5 years (basal cell carcinoma of the skin
             excluded).

          -  No central nervous system or cerebrospinal fluid involvement

          -  No other investigational drugs received within 30 days prior to being registered for
             protocol therapy.

          -  No active infections.

          -  No current breastfeeding